Following a clinical trial update press release on March 15th 2013, the stem cell company Neuralstem saw limited excitement in the market over its stem cell line NSI-566. While shares have moved off their lows for this year, the overall trend is starting to look a bit bearish.
http://seekingalpha.com/article/1292551-neuralstem-update-fails-to-excite-all-eyes-on-upcoming-phase-ii-trial?source=feed
http://seekingalpha.com/article/1292551-neuralstem-update-fails-to-excite-all-eyes-on-upcoming-phase-ii-trial?source=feed
No comments:
Post a Comment